Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sipuleucel-t + testosterone cypionate
- Development stage
- Unknown
- Lead developer
- Dendreon
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Small Molecules
- Administration
- Intravenous, Intramuscular
01
Overview
Sipuleucel-t + testosterone cypionate is a combination therapy under investigation for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Sipuleucel-t is an autologous active cellular immunotherapy (therapeutic cancer vaccine) that primes a patient’s own immune cells against prostatic acid phosphatase (PAP), a prostate cancer antigen, via ex vivo activation with a recombinant PAP-GM-CSF fusion protein. Testosterone cypionate, an androgen and anabolic steroid, is primarily used to treat hypogonadism and acts as a testosterone replacement agent. Recent clinical trials explore the effect of bipolar androgen therapy (BAT)—cycling supraphysiologic and near-castrate testosterone levels, achieved with testosterone cypionate—in combination with sipuleucel-t to potentiate immune responses and overcome tumor resistance in advanced prostate cancer[4][6][8][9].
- Brand names
- ProvengeDepo-Testosterone
- Other names
- sipuleucel-ttestosterone cypionate
02
Targets
AR (Adrenergic receptors)PAP (Prostatic acid phosphatase)
Beyond the preview
Go deeper on sipuleucel-t + testosterone cypionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sipuleucel-t + testosterone cypionate.